David Alan Urbanek
CIK 1752446 · View on SEC EDGAR ↗
First SEC filing: March 3, 2021 · Latest: March 3, 2021
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Nov. 18, 2019 | ELAN | P | 76 | $26.29 | $1,998 | 76 Indirect | — | Acquired | -7.9% (price as of 2026-08-20) |
| Nov. 18, 2019 | ELAN | P | 76 | $26.27 | $1,997 | 76 Indirect | — | Acquired | -7.8% (price as of 2026-08-20) |
| Nov. 18, 2019 | ELAN | P | 76 | $26.21 | $1,992 | 76 Indirect | — | Acquired | -7.6% (price as of 2026-08-20) |
| March 11, 2019 | ELAN | P | 2,021 | — | — | 14,000 Direct | +16.87% | Acquired | (price as of 2026-08-20) |
| Sept. 24, 2018 | ELAN | P | 500 | $24.00 | $12,000 | 500 Direct | — | Acquired | 0.9% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 1, 2023 | ELAN | Employee Stock Option (right to buy) | Common Stock (60,700) | $11.26 | March 1, 2033 | 60,700 | Acquired |
| March 1, 2022 | ELAN | Employee Stock Option(right to buy) | Common Stock (27,480) | $28.94 | March 1, 2032 | 27,480 | Acquired |
| Oct. 20, 2018 | ELAN | Non-Qualified Stock Option (Right-to-Buy) | Elanco Animal Health Inc. Common Stock (21,086) | $31.61 | Oct. 20, 2028 | 21,086 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
ELAN
President, Manufacturing and Quality| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | — | — | — | — | — | — | — | — |
| 2018 | — | — | — | — | — | — | — | — |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.